Table 2.

Multivariate models within proximal a and distal tumor site

BiomarkerDFSOSTTR
N (events): 1,389 (477)N (events): 1,389 (365)N (events): 1,389 (417)
HR (95% CI), PHR (95% CI), PHR (95% CI), P
MMR: dMMR vs. pMMR
 Overall0.82 (0.64–1.04), 0.1060.83 (0.63–1.09), 0.1820.71 (0.55–0.93), 0.014
 Proximal0.69 (0.53–0.91), 0.0090.71 (0.53–0.97), 0.0290.57 (0.42–0.78), 0.0004
 Distal1.75 (1.05–2.93), 0.0321.85 (0.99–3.46), 0.0541.86 (1.11–3.12), 0.019
MMR*site interaction P value0.0040.0100.0003
BRAF: mutated vs. nonmutated
 Overall1.36 (1.08–1.71), 0.0091.70 (1.31–2.20), <0.00011.42 (1.11–1.81), 0.005
 Proximal1.35 (1.03–1.76), 0.0281.58 (1.17–2.12), 0.0031.40 (1.05–1.86), 0.024
 Distal1.25 (0.75–2.11), 0.3941.79 (0.99–3.24), 0.0531.42 (0.84–2.39), 0.190
BRAF*site interaction P value0.7070.9030.994
KRAS: mutated vs. nonmutated
 Overall1.45 (1.24–1.69), <0.00011.52 (1.26–1.84), <0.00011.49 (1.27–1.76), <0.0001
 Proximal1.27 (1.03–1.57), 0.0271.25 (0.97–1.60), 0.0791.29 (1.03–1.61), 0.028
 Distal1.66 (1.34–2.07), <0.00011.98 (1.49–2.63), <0.00011.72 (1.37–2.17), <0.0001
KRAS*site interaction P value0.1510.0430.162
  • aAdjusted for age, treatment, sex, t-stage, histologic grade, and nodal status in addition to the variables shown. The results of these variables within site are similar to the overall model.